FDA Determines Regulatory Review Period for Inspire Upper Airway Stimulation System

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the Inspire Upper Airway Stimulation System, a medical device, in accordance with the law, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).